Astrana Health, Inc. 8-K

What Happened

• Astrana Health, Inc. announced its financial results for the quarter and year ended December 31, 2025 via a press release dated March 2, 2026 and scheduled an earnings conference call/webcast for March 2, 2026 at 5:30 a.m. PT / 8:30 a.m. ET. An earnings presentation is available on the company’s investor relations site.
• The company said it will file a Form 12b-25 to extend the deadline for its 2025 Form 10-K and expects to report a material weakness in internal control over financial reporting, expected to relate to acquisition and purchase accounting processes.

Key Details

• Press release and supplemental earnings presentation were furnished with the 8‑K (Exhibits referenced).
• Astrana’s Board increased the maximum aggregate amount available under its existing share repurchase program from $50.0 million to $100.0 million; the authorization has no expiration and may be suspended or changed.
• During the three months ended December 31, 2025, the company repurchased 633,844 shares; as of December 31, 2025, $35.9 million remained available under the repurchase plan.
• The company expects to use the 15‑day extension provided by Rule 12b‑25 and currently anticipates filing the 2025 Form 10‑K within that extension period.

Why It Matters

• Investors get the company’s reported results and an earnings call to hear management’s discussion, but should note the Form 12b‑25 extension and the disclosed anticipated material weakness in controls—this may affect the timing and review of the audited 2025 financial statements.
• The larger $100M repurchase authorization signals management’s option to return more capital to shareholders, though repurchases depend on market conditions, liquidity, and compliance with covenants and can be paused or stopped at any time.